Author: xnewsline

mHSPC and ARPI Treatment Intensification: Interpreting 2026 Data for Prostate Cancer Disease Control

Metastatic hormone-sensitive prostate cancer (mHSPC) is a stage of prostate cancer in which metastatic disease is present but tumor growth remains initially dependent on androgen signaling. Standard androgen deprivation therapy (ADT)—achieved via luteinizing hormone–releasing hormone (LHRH) agonists/antagonists or surgical castration—reduces circulating testosterone…Read More »